Tags: Cancer | cancer | vaccine | survival | progression | metastatic | spread

Cancer Vaccines Promise to Boost Survival

By    |   Monday, 06 April 2015 03:45 PM

New leading-edge anti-cancer vaccines are proving to extend the lives of patients, even when they don’t have a clear and obvious impact on the spread of tumors, a new analysis shows.

Therapeutic vaccines have been developed to treat advanced prostate and melanoma skin cancers that have migrated to other parts of the body.

While those vaccines — which aim to boost the immune system to fight cancer — rarely have a noticeable effect on the tumors, a spate of new research has linked them linked with a statistically significant increase in patient survival, researchers said.

In a new analysis published in the journal Cancer Biotherapy and Radiopharmaceuticals, Robert O. Dillman, M.D. — with NeoStem, Inc. — suggests "overall survival" rather than "progression-free survival" should be the gold standard for evaluating the efficacy of cancer vaccines in clinical trials.

In the article — "Cancer Vaccines: Can They Improve Survival?" — Dr. Dillman differentiates between the two key criteria typically used to assess therapeutic cancer vaccines in clinical studies.

Since the vaccines are designed to stimulate an immune response to cancer cells and induce long-term targeting of tumors, they may improve overall survival even if they do not appear to slow the progression of disease, he argues.

Although measuring overall survival compared to progression-free survival would usually require longer clinical trials, overall survival may be the only relevant efficacy endpoint, he concludes.

"This is a timely article considering the number of vaccine and antibody immunotherapy trials ongoing or planned," says Donald J. Buchsbaum, an editor with the journal a cancer radiation specialist with the University of Alabama at Birmingham. "The conclusion that overall survival is the best clinical endpoint for efficacy in therapeutic vaccine and antibody immunotherapy trials in patients with metastatic cancer is based on an analysis of four completed trials."


© 2021 NewsmaxHealth. All rights reserved.


Health-News
Leading-edge anti-cancer vaccines are proving to extend the lives of patients, even when they don't have a clear and obvious impact on the spread of tumors, a new analysis shows.
cancer, vaccine, survival, progression, metastatic, spread
295
2015-45-06
Monday, 06 April 2015 03:45 PM
Newsmax Media, Inc.
 
Newsmax TV Live

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved